BioNxt Solutions Inc. (CVE:BNXT) | WebDisclosure

Switch to English

9807	Sociétés
196790	Mots-clés
127791	Articles
104620	Communiqués

Accueil
Sociétés
BioNxt Solutions Inc.

COMMUNIQUÉ DE PRESSE

publié le 01/12/2025 à 09:05, il y a 2 mois 4 jours

BioNxt Signs Letter Agreement to Acquire 100% Interest in IP and to Codevelop a Sublingual Drug Formulation for Chemotherapy and Immunosuppressant Treatments
BioNxt Solutions collaborates with European chemotherapy company for novel sublingual drug formulation with high-potency ingredient. Focus on oncology and immunosuppressant treatments. Company plans to expand IP portfolio

Oncology BioNxt Solutions European Chemotherapy Company Sublingual Drug Formulation Immunosuppressant
BRÈVE

publiée le 20/11/2025 à 09:10, il y a 2 mois 15 jours

BioNxt Receives Eurasian Patent for Sublingual Cladribine Platform

Global Market Autoimmune Diseases Patent Grant BioNxt Solutions Sublingual Cladribine
BRÈVE

publiée le 20/11/2025 à 09:10, il y a 2 mois 15 jours

BioNxt obtient un brevet eurasien pour sa plateforme de cladribine sublinguale

Marché Mondial Maladies Auto-immunes Solutions BioNxt Cladribine Sublinguale Brevet Accordé
COMMUNIQUÉ DE PRESSE

publié le 20/11/2025 à 09:05, il y a 2 mois 15 jours

BioNxt Secures Final Patent Grant from the Eurasian Patent Organization for Sublingual Cladribine Platform
BioNxt Solutions Inc. receives Eurasian Patent No. 051510 for sublingual anticancer drug delivery system, a key milestone in global IP strategy. Expansion to EU and US markets in progress

BioNxt Solutions Inc. Sublingual Delivery Eurasian Patent Pharmaceutical Markets Global IP Strategy
BRÈVE

publiée le 04/11/2025 à 09:10, il y a 3 mois 1 jour

BioNxt Receives European Patent Notification for Cladribine Thin-Film

Multiple Sclerosis Oral Therapies Cladribine European Patent BioNxt
BRÈVE

publiée le 04/11/2025 à 09:10, il y a 3 mois 1 jour

BioNxt reçoit une notification de brevet européen pour son film mince de cladribine

Sclérose En Plaques Thérapies Orales Cladribine Brevet Européen BioNxt
COMMUNIQUÉ DE PRESSE

publié le 04/11/2025 à 09:05, il y a 3 mois 1 jour

BioNxt Reports "Intention to Grant" Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film as the Multiple Sclerosis Market Shifts Toward Patient-Friendly Therapies
BioNxt Solutions Inc. receives 'Intention to Grant' notification from European Patent Office for sublingual cladribine thin-film formulation for MS treatment, securing extensive IP protection across Europe and Eurasia

BioNxt Solutions Inc. European Patent Office MS Treatment Sublingual Thin-Film Global Patent Coverage
BRÈVE

publiée le 30/10/2025 à 08:10, il y a 3 mois 6 jours

BioNxt Solutions Inc. fait progresser un brevet pour l'administration de médicaments anticancéreux

Sclérose En Plaques Solutions BioNxt Administration De Médicaments Brevet Eurasien Stratégie En Matière De Brevets
BRÈVE

publiée le 30/10/2025 à 08:10, il y a 3 mois 6 jours

BioNxt Solutions Inc. Advances Patent for Cancer Drug Delivery

Multiple Sclerosis Drug Delivery BioNxt Solutions Eurasian Patent Patent Strategy
COMMUNIQUÉ DE PRESSE

publié le 30/10/2025 à 08:05, il y a 3 mois 6 jours

BioNxt Reports "Readiness to Grant" Patent Notification from the Eurasian Patent Organization
BioNxt Solutions Inc. receives "Readiness to Grant" notification from EAPO for comprehensive patent application on sublingual delivery of anticancer drugs for autoimmune neurodegenerative diseases, including lead product BNT23001 for MS treatment. Patent protection strengthens commercialization strategy

BioNxt Solutions Inc. Patent Application Sublingual Drug Delivery Anticancer Drugs EAPO

Les Echos

Publié le 05/02/2026 à 11:30, il y a 2 heures 45 minutes

Déclaration nombre d'actions et droits de vote - 05.02.2026
Publié le 05/02/2026 à 11:30, il y a 2 heures 45 minutes

Disclosure of shares outstanding and voting rights - 05.02.2026
Publié le 04/02/2026 à 18:04, il y a 20 heures 11 minutes

Capital et droits de vote au 31 janvier 2026
Publié le 04/02/2026 à 18:04, il y a 20 heures 11 minutes

Total number of voting rights and shares making up the share capital at January 31, 2026
Publié le 04/02/2026 à 17:45, il y a 20 heures 30 minutes

Information concerning the total number of voting rights and shares 2026 01 31

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 05/02/2026 à 14:00, il y a 15 minutes

Organto Foods Inc. Expects Strong 2026 Growth Driven by Retail Wins and Expanded Supply Partnerships
Publié le 05/02/2026 à 14:00, il y a 15 minutes

Tectonic Metals Drills 272 Metres of 0.50 g/t Au and 277 Metres of 0.49 g/t Au; Confirms Bulk-Tonnage Potential at Heap-Leachable Chicken Mountain, Flat Gold Project, Alaska
Publié le 05/02/2026 à 13:30, il y a 45 minutes

Nextech3D.ai to Report Q3 2025 Earnings After Market Close on February 18, 2026
Publié le 05/02/2026 à 13:30, il y a 45 minutes

ESGold Expands Montauban Land Position Following 3D Geological Model Identifying Potential District-Scale Mineralized Corridor
Publié le 05/02/2026 à 13:20, il y a 55 minutes

Guanajuato Silver Sees Significant Growth in Resources at Valenciana

Voir tout ACCESSWIRE

EQS Group

Publié le 05/02/2026 à 14:00, il y a 15 minutes

Gurit Expands U.S. Operations to Support Growing Subsea Demand
Publié le 05/02/2026 à 13:30, il y a 45 minutes

Ascory Bank ends its year of transformation in 2025 with positive results and starts 2026 with a new strategy and a new name
Publié le 05/02/2026 à 13:04, il y a 1 heure 11 minutes

EQS-Adhoc: Ascory Bank AG raises earnings forecast for financial year 2025
Publié le 05/02/2026 à 12:48, il y a 1 heure 26 minutes

Turkiye Garanti Bankasi A.S.: Announcement regarding forward looking statements on the expectations for the year 2026
Publié le 05/02/2026 à 12:45, il y a 1 heure 30 minutes

R.E.A. Holdings plc: Notification of Major Holdings